廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,041.17
    +30.50 (+1.01%)
     
  • 滬深300

    3,537.48
    +16.52 (+0.47%)
     
  • 美元

    7.8254
    -0.0002 (-0.00%)
     
  • 人民幣

    0.9221
    -0.0007 (-0.08%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0515
    +0.0001 (+0.10%)
     
  • 歐元

    8.4415
    +0.0009 (+0.01%)
     
  • 英鎊

    9.8890
    +0.0130 (+0.13%)
     
  • 紐約期油

    83.11
    -0.06 (-0.07%)
     
  • 金價

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin

    69,876.30
    -1,191.98 (-1.68%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure

  • Merrimack Pharmaceuticals Inc's (NASDAQ: MACK) partner announced that Ipsen SA (OTC: IPSEY) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC).

  • The study did not meet the primary endpoint of overall survival in patients treated with Onivyde versus topotecan.

  • However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed.

  • The safety and tolerability of Onivyde were consistent with its already-known safety profile, and no new safety concerns emerged.

  • The clinical study results will be communicated with the regulatory agency." 

  • Ipsen indicated in its update that it would analyze the data further before making decisions about the next steps.

  • "We will continue to monitor updates from Ipsen regarding the SCLC program," said Gary Crocker, Chairman, and CEO of Merrimack Pharmaceuticals.

  • Ipsen expects to publicly report its top-line data from its continuing Phase 3 study of Onivyde in first-line pancreatic ductal adenocarcinoma before the end of 2022.

  • Price Action: MACK shares are down 13.30% at $4.32 during the market session on the last check Wednesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.